Bioregulator ResearchRead More →
Vilon Research
An evidence-led look at Vilon research: how independent the literature is, animal findings including an adverse one, and a computational DNA mechanism.
Dr. Tharindunee Jayakody
August 27, 2026
Bioregulator Research
Prostamax Research
Dr. Tharindunee JayakodyPhDPublished 27 August 2026
Prostamax is a short synthetic peptide, one of a set of compounds marketed as "peptide bioregulators" and developed at the St Petersburg Institute of Bioregulation and Gerontology. Its published record is very small. This page sets out what that record does and does not show.
Conflict of interest is a recurring theme in this literature, and it is set out below. Research-grade Prostamax is supplied for laboratory research use only.
The clearest compound-specific result is a safety signal
The most concrete published finding for Prostamax is not an efficacy result. It is a marker of DNA damage.
In a 2012 in vitro study, Prostamax was applied to lymphocyte cultures from donors aged 75 to 86 [1]. Sister chromatid exchange roughly doubled, from 5.9 to 12.0 exchanges per cell [1].
The authors read this as beneficial chromatin decondensation. In standard genetic toxicology, elevated sister chromatid exchange is a conventional biomarker of genotoxic stress. That paper reported no genotoxicity assessment, and no follow-up study appears in the indexed literature.
This is cell-culture work on cells taken from people. It is not a study of anyone's health. It should not be read as evidence of harm or of benefit in a living person. It is an unresolved signal.
Identity: a defined peptide, not a prostate extract
Prostamax is a defined synthetic tetrapeptide, four amino acids long, Lys-Glu-Asp-Pro, written KEDP [1]. It is not an extract of prostate tissue, which is the most common assumption made about it.
The NLM authority record C500342 maps the name Prostamax to lysyl-glutamyl-aspartyl-proline, written H-Lys-Glu-Asp-Pro-OH. The PubChem record named Prostamax is CID 9848296, CAS 473578-47-1, molecular formula C20H33N5O9.
Two related Russian preparations, Prostatilen and Libidon, genuinely are tissue extracts. They are separate products, and their literature does not belong to Prostamax. The institute's own 2022 review spells it "Prostomax" with an o in Table 2 [5], which matters when searching.
Prostamax also sits inside a nested series. It shares its first two residues with a dipeptide in that same table [5]. Its first three residues form a tripeptide that NLM records separately as vesugen. No published study compares them directly. The literature therefore offers no basis for saying what functionally separates them, and on that point it is simply silent.
Who produced this literature
A PubMed search under the name returned six records in August 2026. Every one of them is cell or tissue culture work.
Four are studies of human lymphocyte cultures: the 2012 cytogenetics paper, two microcalorimetry studies, and a 2004 chromatin study [1][2][3][9]. Another tested Prostamax on rat tissue explants alongside three sibling peptides, at a single concentration, with no dose-response and no blinding described in the abstract [4].
Most of the Prostamax literature comes from one group at Tbilisi State University. The rat explant study is from the originating institute itself [4]. The 2004 chromatin study has the institute's founder as first author [9]. The Tbilisi group is a collaborator rather than an outside replicator, having co-published with that founder in 2004 [6]. Most of its output sits in a single low-visibility journal, and several of these articles are Russian-language with English abstracts only.
The institute developed, patented and sells these compounds. Papers from its network declare no conflict of interest, including a 2020 statement that each author has no "patent/licensing arrangement" [8].
What has not been studied
There is no clinical trial of Prostamax in people. A ClinicalTrials.gov search on 27 August 2026 returned no registered study of it.
There is no whole-animal study of Prostamax. The rat work is explant tissue in a dish, not a living animal, and there is no lifespan or survival data for this compound in any species.
No pharmacokinetic study of Prostamax has been located in the indexed literature, in humans or in animals. No study has measured whether it survives digestion or reaches the bloodstream intact. PepT1, the intestinal transporter for small peptides, transports di- and tripeptides only [7]. Prostamax is a tetrapeptide, so it has no known carrier-mediated intestinal route. That is an inference from transporter specificity rather than an experiment on this compound.
No formal toxicology package has been published for Prostamax. Absence of published toxicology is not evidence of safety.
Frequently Asked Questions
Is there any human data on Prostamax?
There is no clinical study of Prostamax in people. The only human material anywhere in its literature is lymphocyte cultures taken from donors and studied in a dish [1][2][3][9]. Cells from people are not the same as treating people. A ClinicalTrials.gov search on 27 August 2026 returned no registered study of this compound.
Is Prostamax an extract of prostate tissue?
No. It is a defined synthetic tetrapeptide, Lys-Glu-Asp-Pro [1], carried in PubChem as CID 9848296 with CAS 473578-47-1. Two other Russian preparations, Prostatilen and Libidon, genuinely are tissue extracts, and they are commonly confused with it. Their literature does not apply to Prostamax.
What did the sister chromatid exchange finding show?
In lymphocyte cultures from donors aged 75 to 86, sister chromatid exchange roughly doubled, from 5.9 to 12.0 exchanges per cell [1]. The authors interpreted this as beneficial chromatin decondensation, while elevated sister chromatid exchange is conventionally read as a marker of genotoxic stress. That paper reported no genotoxicity assessment, and no follow-up appears in the indexed literature. It is an in vitro observation and remains unresolved.
References
- 1Dzhokhadze TA, et al. Georgian Medical News. 2012;(212):76-82. PMID 23221144. Russian language, English abstract.
- 3Meskhi T, et al. Biofizika. 2004;49(6):1091-1093. PMID 15612551. Russian language, English abstract.
- 4Zakutskii AN, et al. Advances in Gerontology (Uspekhi Gerontologii). 2006. PMID 17152728. Russian language, English abstract.
- 5Khavinson V, et al. International Journal of Molecular Sciences. 2022. PMID 35887081. DOI: 10.3390/ijms23147733.
- 9Khavinson VKh, Lezhava TA, Malinin VV. Bulletin of Experimental Biology and Medicine. 2004;137(1):78-81. PMID 15085253.
Reviewed & approved for scientific accuracy
Dr. Tharindunee Jayakody
PhD — Scientific Contributor and Reviewer
Dr Jayakody is a molecular pharmacologist with over 15 years of experience in translating complex research into clear, evidence-based explanations, with expertise on peptide therapeutics and other emerging compounds, particularly in delineating the mechanisms of action of therapeutics. As a contributor to research-focused platforms, Dr Jayakody aims to give scientifically literate readers a balanced view of what current data can and cannot support, helping them understand how promising findings in the lab translate, or sometimes fail to translate, into real-world applications.
View team profile →Related Articles
Bioregulator ResearchRead More →
Vesugen Research
An evidence-led look at Vesugen research: identity and naming, its presence inside four other products, and two uncontrolled human reports.
Dr. Tharindunee Jayakody
August 27, 2026
Bioregulator ResearchRead More →
Thymalin Research
An evidence-led look at Thymalin research: what the preparation actually is, the COVID-19 trial, the older human literature, and what is unproven.
Dr. Tharindunee Jayakody
August 27, 2026